Every February 4, World Cancer Day invites us to pause and reflect on a phenomenon that can no longer be described solely as a health issue: cancer has become the structural force that most starkly exposes the inequalities of the 21st century. Despite scientific, technological, and therapeutic advances, the reality is deeply concerning: where a person is born, their socioeconomic status, and their access to healthcare determine not only the likelihood of developing cancer, but also the chances of receiving a timely diagnosis and effective treatment.

The latest evidence from the International Agency for Research on Cancer (IARC) shows that in 2022 the world recorded 20 million new cancer cases and 9.7 million deaths, further consolidating cancer as the second leading cause of death globally. But the most alarming issue is not the present—it is the future: by 2050, annual incidence is expected to reach 35 million cases, a 77% increase driven by population aging, accelerated urbanization, and greater exposure to risk factors.

Behind these figures lies a far more complex story than the epidemiological curve alone reveals.

Inequality as an oncological variable

Cancer does not affect everyone equally. The gap between countries—and within countries—is so profound that one could speak of “two parallel oncological realities.”

Countries with low Human Development Index (HDI) are projected to face a 142% increase in cancer cases by 2050, compared to 42% in more developed countries. This means that the burden of cancer will grow three times faster where healthcare systems are already under strain and where diagnostic and treatment infrastructure is insufficient.

Even in developed regions, internal disparities are significant. An OECD report shows that cancer mortality can vary by more than 30% between regions within the same country, influenced by education, income, and service availability. Lung cancer mortality, for instance, can be 2.6 times higher among individuals with lower levels of education.

Inequality also operates at a structural level. A recent WHO study revealed that only 39% of countries finance basic cancer management services within their benefit packages, and just 28% include palliative care as a guaranteed service. This lack of public funding transforms cancer into a disease with a direct impact on household financial stability.

Radiotherapy, surgery, and medicines: the missing pillars

One of the most critical findings emerging from recent scientific literature is the global inaccessibility of essential treatments. While oncology innovation has advanced more in the past decade than in the previous 50 years, much of the world remains trapped in a system where even the basics are not guaranteed.

The Lancet Oncology Commission documented that only 10% of cancer patients in low-income countries have access to radiotherapy, despite the fact that between 50% and 70% will require it at some point. This is compounded by a critical shortage of trained personnel, equipment, and referral networks.

In oncological surgery, the situation is similar. The Second Lancet Commission on Global Surgery warned that lack of timely access to curative and palliative surgery is one of the leading causes of avoidable cancer mortality, and proposed a framework of eight actions to close the surgical gap—from financing to capacity building.

In terms of medicines, the outlook is even more concerning. The global ESMO study (2023) revealed that 40% of essential chemotherapy drugs in lower-middle-income countries are only available at full cost, pushing millions of families into catastrophic health expenditure. Furthermore, a recent Lancet editorial pointed out that there is not even a global system of metrics to monitor availability, pricing, or continuity of supply for essential cancer medicines—describing this as a structural failure of the global health system.

The other face of cancer: youth, epidemiological transition, and the environment

Peer-reviewed studies show a significant increase in cancer among young adults, particularly breast, colorectal, and certain gastrointestinal cancers. This phenomenon, described by the Global Burden of Disease (GBD) 2023, is attributed to new exposures: obesity, more processed diets, alcohol consumption, sedentary lifestyles, and pollution.

This epidemiological transition demands new models of prevention and public policy adapted to urban, occupational, and digital realities that did not exist two decades ago.

Prevention: the most powerful—and most underutilized—tool

Despite the prevailing narrative of helplessness surrounding cancer, a significant proportion is preventable. A global study published in The Lancet confirms that 41.7% of cancer deaths are linked to known risk factors such as tobacco, alcohol, obesity, physical inactivity, and pollution.

The WHO adds that up to 50% of cancers could be prevented through proven measures, including vaccination against HPV and hepatitis B, reduced tobacco use, healthy nutrition, and weight control.

However, implementation remains far from universal. In subregions of Central Asia, for example, only 1% of eligible girls receive the HPV vaccine, compared to 86% in Australia and New Zealand.

Cancer as a global economic challenge

The economic cost of cancer is enormous. Beyond investments in infrastructure, workforce, and medicines, there are productivity losses associated with premature deaths, disability, and informal caregiving. The Lancet Oncology Commission on radiotherapy estimates that closing the access gap in low- and middle-income countries would generate billions in economic benefits through reduced premature mortality.

This is a critical point for Latin America: every late diagnosis carries not only a human cost, but also a fiscal and macroeconomic one.

Closing the gap: the path is clear

If one conclusion emerges clearly from the scientific literature, it is that the world does not need to wait for more evidence—we already know what works.

The pillars are well established:

• Robust, interoperable, and sustainable cancer registries
• Large-scale, sustained prevention focused on tobacco, infections, obesity, and environmental factors
• Early diagnosis, particularly for breast, colorectal, and cervical cancers
• Universal access to surgery and radiotherapy, with guaranteed financing and human resources
• Continuous availability of essential medicines, without impoverishing out-of-pocket spending

The challenge is not only clinical. It is political, economic, and ethical.

A final call

Cancer lays bare the deepest inequalities: between countries, regions, genders, and levels of education. The fight against cancer will not be won solely in laboratories, but in public budgets, regulatory policies, health infrastructure, and our collective capacity to act.

Each country has unique challenges. But the urgency is shared. And if World Cancer Day teaches us anything, it is that equity is not an abstract concept—it is the difference between life and death for millions of people.

References:

1. International Agency for Research on Cancer (IARC). Global cancer burden growing, amidst mounting need for services. WHO News Release, 1 Feb 2024.
2. Bizuayehu HM, Ahmed KY, Kibret GD, et al. Global Disparities of Cancer and Its Projected Burden in 2050. JAMA Network Open. 2024;7(11):e2443198.
3. GBD 2023 Cancer Collaborators. The global, regional, and national burden of cancer, 1990–2023, with forecasts to 2050. The Lancet. 2025;406:1565–1586.
4. Organisation for Economic Co-operation and Development (OECD). Inequalities in cancer: a major public health concern. The Lancet Public Health. 2024;9(3):e147.
5. World Health Organization (WHO). Global cancer burden growing, amidst mounting need for services. Survey on UHC & Cancer, 2024.
6. Olivia Newton-John Cancer Research Institute / Lancet Oncology Commission. Global disparities in access to radiotherapy and theranostics. 2024.
7. Are C, Schissel M, Murthy S. Lancet Oncology Commission on Global Cancer Surgery — Access to Cancer Surgery. Annals of Surgical Oncology. 2025;32:42–46.
8. Cherny NI, Trapani D, Galotti M, et al. ESMO Global Consortium Study on the availability and accessibility of cancer medicines: 2023 update. Annals of Oncology. 2025; p.247–262.
9. Jenei K, Sullivan R. Cancer medicines remain absent from global access metrics. The Lancet. 2026;407(10527):491–492.
10. GBD 2023 Cancer Collaborators. Global cancer burden: progress, projections, and challenges. The Lancet. September 24, 2025.
11. Wu Z, Xia F, Lin R. Global burden of cancer and associated risk factors in 204 countries and territories, 1980–2021. Journal of Hematology & Oncology. 2024;17:119.
12. World Health Organization (WHO) – Eastern Mediterranean Regional Office (EMRO). World Cancer Day 2024. 2024.
13. American Cancer Society (ACS). Global Cancer Statistics 2024. CA: A Cancer Journal for Clinicians. Apr 2024.